PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Domperidone - Parkinson's Disease (apomorphine pre-treatment)

PAD Profile : Domperidone - Parkinson's Disease (apomorphine pre-treatment)

Keywords :
PD, Nausea and vomiting, MHRA, sickness, emesis, anti-emetic
Brand Names Include :
Motilium

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
04 December 2019
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommends the off label use of domperidone for the treatment of nausea & vomiting  when used in conjunction with apomorphine in Parkinson's Disease patients, only when prescribed within a secondary care setting. Treatment duration is restricted to a maximum of one week in all patients*.

Prescribers should ensure that the patient understands the risks and consents to using domperidone off-label, noting the updated MHRA alert (December 2019) and the MHRA drug safety update (April 2016) in relation to this treatment combination.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication

Domperidone will be considered RED on the traffic light system for this indication.

*MHRA drug safety update (December 2019) https://www.gov.uk/drug-safety-update/domperidone-for-nausea-and-vomiting-lack-of-efficacy-in-children-reminder-of-contraindications-in-adults-and-adolescents

MHRA drug safety update (April 2016) : Apomorphine with domperidone: minimising risk of cardiac side effects https://www.gov.uk/drug-safety-update/apomorphine-with-domperidone-minimising-risk-of-cardiac-side-effects

Associated BNF Codes

04. Central Nervous System
04.06.00. Drugs used in nausea and vertigo
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More